CTOs on the Move

Intralytix

www.intralytix.com

 
Intralytix, Inc. is a biotechnology company focused on the production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Intralytix raised $17.5M on 07/24/2017

Similar Companies

ICON Plc

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies.    In a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis.    We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. We are also an 'end-to-end' Pharmacovigilance service provider and this includes Post Marketing Surveillance activities too.

Pharming

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

Allcells LLC

Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Gyroscope Therapeutics

Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.

NapaJen

A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.